Literature DB >> 11934085

Individual differences in latent neuropsychological abilities at addictions treatment entry.

Marsha E Bates1, Erich W Labouvie, Gerald T Voelbel.   

Abstract

The latent structure of neuropsychological abilities and risk factors for impairment were examined in 197 persons entering addictions treatment. Confirmatory factor analysis yielded 4 factors: Executive, Memory, Verbal, and Processing Speed. The measurement model was consistent with evidence that neuropsychological test performance is factorially complex and supported by multiple brain regions. Path analyses showed that risk factors explained 34%-57% of the true variance in abilities. Age, education, and medical status had the most generalized and robust associations with abilities. Drug use disorder diagnoses, childhood behavior problems, familial alcoholism, and psychopathology were also significantly related to specific latent abilities. Knowledge of neuropsychological impairment may be clinically useful, and selected risk factors may help treatment providers decide which clients should receive formal neuropsychological assessment.

Entities:  

Mesh:

Year:  2002        PMID: 11934085     DOI: 10.1037//0893-164x.16.1.35

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  13 in total

1.  Risk factors and neuropsychological recovery in clients with alcohol use disorders who were exposed to different treatments.

Authors:  Marsha E Bates; Danielle Barry; Erich W Labouvie; William Fals-Stewart; Gerald Voelbel; Jennifer F Buckman
Journal:  J Consult Clin Psychol       Date:  2004-12

2.  Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder.

Authors:  Raj K Kalapatapu; Kevin L Delucchi; Brooke A Lasher; Sophia Vinogradov; Steven L Batki
Journal:  Mil Med       Date:  2013-09       Impact factor: 1.437

3.  Short-term neuropsychological recovery in clients with substance use disorders.

Authors:  Marsha E Bates; Gerald T Voelbel; Jennifer F Buckman; Erich W Labouvie; Danielle Barry
Journal:  Alcohol Clin Exp Res       Date:  2005-03       Impact factor: 3.455

4.  Association of alcohol use biomarkers and cognitive performance in veterans with problematic alcohol use and posttraumatic stress disorder: data from the mind your heart study.

Authors:  Raj K Kalapatapu; Thomas C Neylan; Mathilda C Regan; Beth E Cohen
Journal:  J Addict Dis       Date:  2014

5.  Social support and cognitive impairment in clients receiving treatment for alcohol- and drug-use disorders: a replication study.

Authors:  Jennifer F Buckman; Marsha E Bates; Jon Morgenstern
Journal:  J Stud Alcohol Drugs       Date:  2008-09       Impact factor: 2.582

6.  A Web-Based Behavior Therapy Program Influences the Association Between Cognitive Functioning and Retention and Abstinence in Clients Receiving Methadone Maintenance Treatment.

Authors:  Michelle C Acosta; Lisa A Marsch; Haiyi Xie; Honoria Guarino; Yesenia Aponte-Melendez
Journal:  J Dual Diagn       Date:  2012-10

7.  Self-regulation, daily drinking, and partner violence in alcohol treatment-seeking men.

Authors:  Julie A Schumacher; Scott F Coffey; Kenneth E Leonard; Judith R O'Jile; Noah C Landy
Journal:  Exp Clin Psychopharmacol       Date:  2013-02       Impact factor: 3.157

8.  Reduced cognitive ability in alcohol dependence: examining the role of covarying externalizing psychopathology.

Authors:  Peter R Finn; Martin E Rickert; Melissa A Miller; Jesolyn Lucas; Tim Bogg; Lyuba Bobova; Hope Cantrell
Journal:  J Abnorm Psychol       Date:  2009-02

9.  Effects of alcoholism severity and smoking on executive neurocognitive function.

Authors:  Jennifer M Glass; Anne Buu; Kenneth M Adams; Joel T Nigg; Leon I Puttler; Jennifer M Jester; Robert A Zucker
Journal:  Addiction       Date:  2009-01       Impact factor: 6.526

10.  Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.

Authors:  Pekka Rapeli; Carola Fabritius; Hely Kalska; Hannu Alho
Journal:  BMC Clin Pharmacol       Date:  2011-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.